Hesperos, Inc. (HESP)
Hesperos will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap | n/a |
Revenue (ttm) | 5.11M |
Net Income (ttm) | -773,316 |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Open | n/a |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | n/a |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About HESP
Hesperos, Inc. is a socially-conscious company that uses our non-invasive, serum-free, multi-organ chip platform (Human-on-a-Chip) systems to provide pre-clinical analytical services with the goal of accelerating drug discovery and general toxicology testing and reducing use of animal testing. Our Human-on-a-Chip platform system mimics the process of initial patient evaluation during a clinical trial, where functional human in vitro tissues are evaluated similar to a patient undergoing medical testing to determine baseline performance metrics. ... [Read more...]
Industry
Health Care
Founded
2015
CEO
James F. Kronauge, Jr., Ph.D.
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
HESP
Financial Performance
Financial StatementsNews
Hesperos IPO Registration Document (S-1)
Hesperos has filed to go public with an IPO on the NASDAQ.